Sensei launches diabetes iPhone app

Share this article:
Sensei launches diabetes iPhone app
Sensei launches diabetes iPhone app

Sensei, a mobile technology developer and subsidiary of Humana, has launched an iPhone application for patients with diabetes.


The diabetes “app,” in Apple parlance, is called My Diabetes Guide, and helps diabetics manage their condition by offering instructions on “what to do, what to know, what to eat and what to ask their doctors,” according to a company statement. Speaking on the need for a mobile diabetes management tool, Robert Schwarzberg, president and CEO, Sensei, said: "Programs online have extensive and valuable content with less a focus and access to the seamless activity we hope to participate in. Lifestyle change isn't what happens while sitting in front of your PC." Patients can download the app for 99 cents through Apple's iTunes app store. 

To help facilitate the patient/physician relationship, My Diabetes Guide offers checklists of items to bring and questions to ask, as well as what to expect at a check-up. Regarding potential partnerships with pharma, Schwarzberg said the company is "in discussions to customize the program for other stakeholders addressing their needs and interests including availability on most handsets.  These new tools of engagement we believe will enhance compliance and brand loyalty." Schwarzberg was not at liberty to comment on any current partnerships with pharmaceutical or medical device marketers.

Lifescan, a subsidiary of Johnson & Johnson, recently debuted a prototype application for the iPhone that would synch glucose meter readings with the iPhone, allowing diabetes patients to manage their blood sugar on the device.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...